Oxford Biomedica and Santen sign ophthalmology R&D deal

UK biotech Oxford Biomedica and Japanese Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease. Inherited retinal diseases are a group of rare disorders caused by one of more than 260 different genes where mutation results in vision loss or blindness, often disproportionally affecting

Continue Reading

Gene therapy medication, Spinraza, provides improvements for patients with spinal muscular atrophy

Spinraza has provided significant improvements in cases with the next most severe form of the neuromuscular disease, spinal muscular atrophy (SMA), which affects children aged from 6 to 18 months.   “The effects are convincing, and this reinforces results from the earlier study,” says Mar Tulinius, Professor of paediatrics at Sahlgrenska Academy and chief medical

Continue Reading